Revvity Raclopride, -, 250µci (9.25mbq)

Revvity Raclopride is a synthetic compound that acts as a selective antagonist at dopamine D₂ receptors. These receptors are potential drug targets for schizophrenia, Parkinsons disease, and other neurological conditions. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity References for NET975: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Sørensen, g., Sager, T.N., Petersen, J.H. et Al. Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice, Psychopharmacology (2008) 199: 37-46.Chen, J., Su, H., Huang, L., Hsieh, M. Reductions in binding and functions of D2 dopamine receptors in the rat ventral striatum during amphetamine sensitization, Life Sciences (1998) 64 (5): 343-354.